North Immunology is a privately held biotechnology company developing bispecific antibodies targeting orthogonal inflammatory pathways in immune and inflammatory diseases. Its lead program is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 and non-type 2 inflammation driving atopic dermatitis.